KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Regeneron Pharmaceuticals (REGN) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Regeneron Pharmaceuticals (REGN) over the last 17 years, with Q4 2025 value amounting to $844.6 million.

  • Regeneron Pharmaceuticals' Profit After Tax fell 796.56% to $844.6 million in Q4 2025 from the same period last year, while for Dec 2025 it was $4.5 billion, marking a year-over-year increase of 209.17%. This contributed to the annual value of $4.5 billion for FY2025, which is 209.17% up from last year.
  • Regeneron Pharmaceuticals' Profit After Tax amounted to $844.6 million in Q4 2025, which was down 796.56% from $1.5 billion recorded in Q3 2025.
  • In the past 5 years, Regeneron Pharmaceuticals' Profit After Tax ranged from a high of $3.1 billion in Q2 2021 and a low of $722.0 million during Q1 2024
  • Its 5-year average for Profit After Tax is $1.3 billion, with a median of $1.1 billion in 2021.
  • In the last 5 years, Regeneron Pharmaceuticals' Profit After Tax soared by 24535.83% in 2021 and then tumbled by 7250.31% in 2022.
  • Over the past 5 years, Regeneron Pharmaceuticals' Profit After Tax (Quarter) stood at $2.2 billion in 2021, then crashed by 46.29% to $1.2 billion in 2022, then fell by 3.13% to $1.2 billion in 2023, then fell by 20.86% to $917.7 million in 2024, then fell by 7.97% to $844.6 million in 2025.
  • Its Profit After Tax was $844.6 million in Q4 2025, compared to $1.5 billion in Q3 2025 and $1.4 billion in Q2 2025.